Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 13 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SpectronRx Europe from Grimbergen, company number BE1006683123, closed financial year 2025 with a result of € -97,901 after tax. For that financial year SpectronRx Europe recorded a gross margin of € -97,189 and equity of € -117,302. Compared with financial year 2024, the result moved from € -39,474 to € -97,901. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.
€ -117,302
▼ € 97,901 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -97,901
▼ 148 % more loss than in 2024
Profit after tax over the fiscal year.
€ 39,653
▲ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -137,375.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 109
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -39,099 | € -97,189 | ▼ € 58,090 |
| Profit after taxes | € -39,474 | € -97,901 | ▼ € 58,426 |
| Equity | € -19,402 | € -117,302 | ▼ € 97,901 |
| Total debts | € 46,216 | € 316,235 | ▲ € 270,019 |
| Cash | € 22,943 | € 39,653 | ▲ 73% |
| Retained profit | € -39,474 | € -137,375 | ▼ € 97,901 |
| Balance sheet total | € 26,814 | € 198,933 | ▲ € 172,118 |
Key figures of SpectronRx Europe, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SpectronRx Europe?
What happened at SpectronRx Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 97,901. Source: NBB ↗
- New establishment in Grimbergen. KBO
- Start of the company according to the CBE. KBO
- Syed Anwer Rizvi became a director. NBB
- Kelli Lightfoot became a director. NBB
- John Zehner became a director. NBB
In short
From € 39,474 loss in 2024 to € 97,901 loss in 2025.
A new publication or filing at SpectronRx Europe? We notify you, reason included.
Follow SpectronRx EuropeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind SpectronRx Europe are Syed Anwer Rizvi, Kelli Lightfoot and John Zehner.
Directors
According to the 2025 annual accounts
Syed Anwer Rizvi
Director
since 2024
Kelli Lightfoot
Director
since 2024
John Zehner
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Beigemsesteenweg 3
1850 Grimbergen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1006.683.123
- VAT number
- BE 1006.683.123
- Registered office
- Beigemsesteenweg 3, 1850 Grimbergen
- Names & denominations
- SpectronRx Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 March 2024
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van overige farmaceutische producten
Groothandel in farmaceutische en medische artikelen